MENU

• New Products

• Projects Under development

• Seeking  Products and capabilities

• Offering Products and capabilities

• Sourcing finished dosages for comparative clinical trials

• Toll production (GMP) of R&D and clinical trial lots

• Our Values

    NEWS

    MAX Pharma Canada Inc. starts using the Dun & Bradstreet's D-U-N-S® Number (Data Universal Numbering System)

    MAX Pharma Canada Inc. receives US FDA labeler code

    MAX Pharma Canada Inc. acquires four product registrations for Canada. DIN transfer process is under way with Health Canada

ONCOLOGY APIs

We assume no liability or responsibility for any infringement of product patents or other rights existing in the intended markets. It is the responsibility of the purchaser to verify and clear the patent position in the country(ies) concerned. The sale of certain products may be subject to specific controls and/or legal requirements or even prohibited and such status must be verified and adhered to by the purchaser

• 5-Fluoro uracil
• AnastrOzole

• Bicalutamide

• Capecitabine
• Carboplatin
• Cisplatin
• Decarbazine

• Docetaxel

• Gemcitabine HCl

• Irinotecan HCl
• Letrozole

• Oxaliplatin

• Paclitaxel
• Pemetrexed DiNa
• Temazolamide
• Thalidomide

See {PDF} list of major items